•  
  •  
 

Abstract

Estrogen receptor-positive (ER+) breast cancer, characterized by estrogen receptor presence on cancer cells, is commonly treated with endocrine therapy. This approach inhibits cancer cell growth by disrupting hormonal signaling, either by blocking estrogen receptors or by inhibiting estrogen production. Nevertheless, when administered as a standalone intervention, this therapy exhibits limited success in treating breast cancer and is often used as adjuvant or neoadjuvant therapy. The p53 protein is crucial for inhibiting cancer development. Ongoing research explores the potential of p53-based treatments by addressing challenges arising from degradation and mutations of p53. Here, we aim to explore the potential of combining endocrine therapy with p53-based treatments in ER+ breast cancer treatment. We extend an existing mathematical model that accounts for the interactions between cancer cells, the estrogen hormone, and the p53 protein. We use optimal control theory to optimize the benefits of treatment of ER+ breast cancer with a combination of p53 and endocrine-based therapies. Our results highlight the benefits of adding p53-based treatment to endocrine therapy in adjuvant and neoadjuvant therapies. Notably, in neoadjuvant endocrine therapy, our results show that the time needed to reach a suitable size for breast-conserving surgery (BCS) is in line with current findings. More importantly, the addition of p53-based therapy may lead to a significant reduction in the time required to reach a suitable size for BCS.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.